Structure of Stiripentol
CAS No.: 49763-96-4
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
Stiripentol is an antiepileptic drug that can inhibit the synaptosomal uptake of GABA, increase the activation of GABAA receptors, it's also a microsomal cytochrome P450 (CYP) isoforms CYP3A4, CYP1A2, and CYP2C19 inhibitor.
Synonyms: BCX2600
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 49763-96-4 |
Formula : | C14H18O3 |
M.W : | 234.29 |
SMILES Code : | CC(C)(C)C(O)/C=C/C1=CC=C(OCO2)C2=C1 |
Synonyms : |
BCX2600
|
MDL No. : | MFCD00869310 |
InChI Key : | IBLNKMRFIPWSOY-FNORWQNLSA-N |
Pubchem ID : | 5311454 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302 |
Precautionary Statements: | P280-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
Raw264.7 macrophages | 5 μM | 24 h | Impaired CT2A CM-induced macrophage migration | PMC10914854 |
Raw264.7 macrophages | 10 μM | 24 h | Inhibited CT2A CM-induced macrophage migration | PMC10914854 |
HepG2 cells | 10 μg/ml | 24 h | Stiripentol combined with siRNA mildly decreased oxalate production in HepG2 cells, suggesting that oxalate synthesis is mostly driven by LDH5 isoenzyme activity | PMC6538379 |
HepG2 cells | 5–100 μg/ml | 24 h | Stiripentol significantly decreased oxalate production in HepG2 cells in a dose-dependent manner | PMC6538379 |
P3 cells | 500 μM | 24 h | Inhibited lactate production, decreased cell respiration, and reduced cell proliferation and invasion | PMC9728051 |
HEK293 cells | 5-300 μM | STP significantly inhibited the peak currents of Cav3.2, with an IC50 value of 64.35 μmol·L–1. | PMC9314114 | |
CHO cells | 5-300 μM | STP significantly inhibited the peak currents of Cav3.1, Cav3.2, and Cav3.3, with IC50 values of 69.16 μmol·L–1, 64.35 μmol·L–1, and 36.6 μmol·L–1, respectively. | PMC9314114 | |
HEK-293T cells | 0.1 μM – 1 mM | 5 s | STP significantly potentiated the response to GABA, with the greatest potentiation observed at α3β3γ2L receptors. | PMC2665930 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Rats | Oxalate excretion model | Oral | 200 mg/kg | Once daily for 48 hours | Stiripentol significantly decreased urine oxalate excretion in rats | PMC6538379 |
Mice | Glioblastoma model | Intraperitoneal injection | 150 mg/kg | Every other day for 6 doses | Impaired tumor growth and extended survival | PMC10914854 |
Mice | P3 tumor model | Intraperitoneal injection | 150 mg/kg | Not specified | Stiripentol treatment significantly increased mouse survival | PMC9728051 |
Rats | Low-dose pentylenetetrazol (PTZ) model and WAG/Rij rat model | Intraperitoneal injection | 150 mg/kg and 300 mg/kg | Single administration, observed for 60 minutes | STP at 300 mg/kg almost completely abolished PTZ-induced SWD and significantly reduced the cumulated duration and number of SWD in WAG/Rij rats. | PMC9314114 |
Rats | KA-induced temporal lobe epilepsy model | Bath application | 100 μM and 300 μM | 20 minutes | Stiripentol significantly increased RED duration at higher concentrations and had minimal effects on RED frequency. | PMC6215509 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03196466 | - | Recruiting | June 2019 | France ... More >> AP-HP Cochin Recruiting Paris, France, 75014 Contact: Jean-Marc Treluyer, M.D., PhD ?? + 00 1 58 41 28 85 ?? jean-marc.treluyer@parisdescartes.fr Less << | |
NCT02926898 | Dravet Syndrome | Phase 3 | Active, not recruiting | December 2018 | United States, California ... More >> University of California San Francisco San Francisco, California, United States, 94143 United States, Colorado The Children'S Hospital Colorado Aurora, Colorado, United States, 80045 United States, Illinois Ann & Robert Lurie Children'S Hospital of Chicago Chicago, Illinois, United States, 60611 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Canada, British Columbia British Columbia Children'S Hospital Vancouver, British Columbia, Canada, V6H3V4 Canada, Quebec Centre Hospitalier Universitaire Sainte-Justine Montreal, Quebec, Canada, H3T 1C5 France Chu Amiens Picardie Service de Neurologie Pediatrique Amiens, France, 80054 CHU DE BORDEAUX Service De Pédiatrie Médicale Bordeaux, France, 33000 CHRU LILLE Centre Hospitalier Régional Universitaire De Lille 2 Lille, France, 59037 H?PITAL FEMME-MèRE-ENFANT H?pital Femme-mère-enfant Service De Neurologie Pédiatrique Lyon, France, 69500 H?pital La Timone, Service de Neurologie Pédiatrique Marseille, France, 13385 H?pital Necker Paris, France, 75743 H?pital Robert Debré Paris, France, 75743 CENTRE REFERENT DES EPILEPSIES Hopital De Hautpierre Strasbourg Cedex, France, F-67098 H?PITAL DES ENFANTS Pédiatrie Toulouse Cedex 9, France, 31059 Hopital Denfants Chru de Nancy Vandoeuvre Les Nancy Cedex, France, 54511 Germany Krankenhaus Mara Ggmbh, Epilepsiezentrum Bethel Bielefeld, Germany, 33617 Universit?tsklinikum Schleswig-Holstein, Klinik Für Neurop?diatrie Kiel, Germany, 24105 Kleinwachau S?chsisches Epilepsiezentrum Radeberg Gemeinnützige Gmbh Radeberg, Germany, 1454 Netherlands Kempenhaeghe Heeze, Netherlands, 5590 Ab Stichting Epilepsie Instellingen Nederland Zwolle, Netherlands, 8025 BV Spain Hospital Sant Joan de Déu Barcelona, Spain, 08950 Hospital Ruber Internacional Primera Planta Servicio de Neurologia Madrid, Spain, 28034 Clinica Universitaria de Navarra Pamplona, Spain, 31008 United Kingdom Institute of Neurosciences Queens Elizabeth University Glasgow, United Kingdom, G51 4TF Alder Hey Children'S Nhs Foundation Trust Liverpool, United Kingdom, L12 2AP Evelina Hospital London, United Kingdom, SE1 7EH Great Ormonnd Street Hospital For Children Nhs Foundation Trust London, United Kingdom, WC1N 3JH Less << |
NCT02607904 | Epilepsy | Phase 2 | Enrolling by invitation | August 2019 | - |
NCT02205931 | Epilepsy | Phase 4 | Recruiting | June 2019 | United Kingdom ... More >> Birmingham Children's Hospital Recruiting Birmingham, United Kingdom, B4 6NH Contact: Shakti Agrawal, MBBS ?? 0044 1213338149 ?? shakti.agrawal@bch.nhs.uk ?? Principal Investigator: Shakti Agrawal, MBBS ?? ?? ?? Bristol Royal Hospital for Children Recruiting Bristol, United Kingdom, BS2 8AE Contact: Andrew Mallick, FRCPCH ?? ?? ?? Principal Investigator: Andrew Mallick ?? ?? ?? Addenbrooke's Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: Alasdair Parker, MA ?? 0044 1223 245151 ?? alasdair.parker@addenbrookes.nhs.uk ?? Principal Investigator: Alasdair Parker, MA ?? ?? ?? Lancashire Teaching Hospitals NHS Foundation Trust Recruiting Lancashire, United Kingdom Contact: Helen Basu ?? ?? Helen.Basu@lthtr.nhs.uk ?? Principal Investigator: Helen Basu ?? ?? ?? Leeds Teaching Hospital Recruiting Leeds, United Kingdom, LS1 3EX Contact: Helen McCullagh, RCPCH ?? 0044 113 243 2799 ?? h.mccullagh@nhs.net ?? Principal Investigator: Helen McCullagh, RCPCH ?? ?? ?? Alder Hey Children's Hospital Recruiting Liverpool, United Kingdom, L12 2AP Contact: Rachel Kneen, BMBS ?? 0044 151 2525163 ?? rachel.kneen@liverpool.ac.uk ?? Principal Investigator: Rachel Kneen, BMBS ?? ?? ?? Great Ormond Street Hospital Recruiting London, United Kingdom, WC1N 3JH Contact: Christin Eltze, MD Res ?? 0044 207 405 9200 ext 5438 ?? christin.eltze@gosh.nhs.uk ?? Principal Investigator: Christin Eltze, MD Res ?? ?? ?? St George's University Hospitals NHS Foundation Trust Recruiting London, United Kingdom Contact: Penny Fallon ?? ?? Penny.Fallon@stgeorges.nhs.uk ?? Principal Investigator: Penny Fallon ?? ?? ?? Royal Manchester Children's Hospital Recruiting Manchester, United Kingdom, M13 0JE Contact: Tim Martland, RCPCH ?? 0044 161 276 1234 ?? timothy.martland@cmft.nhs.uk ?? Principal Investigator: Tim Martland, RCPCH ?? ?? ?? The Newcastle Upon Tyne Hospitals NHS Foundation Trust Recruiting Newcastle upon Tyne, United Kingdom Contact: Anita Devlin ?? ?? Anita.Devlin@nuth.nhs.uk ?? Principal Investigator: Anita Devlin ?? ?? ?? Sheffield Children's NHS Foundation Trust Recruiting Sheffield, United Kingdom Contact: Archana Desurkar ?? ?? Archana.Desurkar@sch.nhs.uk ?? Principal Investigator: Archana Desurkar Less << |
NCT02607891 | Epilepsy | Phase 2 | Recruiting | August 2018 | France ... More >> Not yet recruiting Elancourt, France Not yet recruiting Paris, France Not yet recruiting Rennes, France Netherlands Not yet recruiting Zwolle, Netherlands Poland Not yet recruiting Kraków, Poland Romania Not yet recruiting Bucuresti, Romania Spain Recruiting Barcelona, Spain Recruiting Madrid, Spain Recruiting Sevilla, Spain Sweden Recruiting Goteborg, Sweden Less << |
NCT01983722 | Dravet Syndrome | APPROVED_FOR_MARKETING | - | Cincinnati Children's Hospital... More >> Medical Center, Cincinnati, Ohio, 45229, United States Less << | |
NCT02239276 | Dravet Syndrome|Epileptic Ence... More >>phalopathies Associated With SCN1A Mutations Less << | NO_LONGER_AVAILABLE | - | Cook Children's Medical Center... More >>, Fort Worth, Texas, 76104, United States Less << | |
NCT01835314 | Dravet Syndrome | NO_LONGER_AVAILABLE | - | Children's Hospital Colorado, ... More >>Aurora, Colorado, 80045, United States Less << | |
NCT01533506 | - | - | February 2013 | United States, Minnesota ... More >> Mayo Clinic in Rochester Rochester, Minnesota, United States, 55905 Less << | |
NCT05419180 | Pharmacoresistant Focal Epilep... More >>sies Less << | PHASE4 | COMPLETED | 2024-06-13 | Centre de Référence Epilepsies... More >> Rares / Centre Investigation Clinique (CIC) - H?pital Necker-Enfants Malades, Paris, 75015, France Less << |
NCT06540378 | Status Epilepticus | COMPLETED | 2025-05-24 | - | |
NCT03866928 | Healthy Volunteers | PHASE1 | COMPLETED | 2019-04-05 | ATC, Liège, Belgium |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
4.27mL 0.85mL 0.43mL |
21.34mL 4.27mL 2.13mL |
42.68mL 8.54mL 4.27mL |
Tags: Stiripentol | BCX2600 | BCX 2600 | BCX-2600 | Cytochrome P450 | CYPs | cytochrome P450 inhibitor | CYP3A4 inhibitor | CYP1A2 inhibitor | CYP2C19 inhibitor | CYP3A4 inhibition | anticonvulsant | GABAergic modulation | seizure control | 49763-96-4
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL